Marion Subklewe
Advanced in Wilms Tumor

Marion Subklewe

Munich, BY, DE 
Advanced in Wilms Tumor
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Marion Subklewe practices in Munich, Germany. Ms. Subklewe is rated as an Advanced expert by MediFind in the treatment of Wilms Tumor. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 226 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Wilms Tumor.

Gender
Female

Locations

Munich, BY, Germany
Other Locations
Heidelberg, BW, Germany
Essen, NW, Germany
Erlangen, BY 91054, Germany
Maximilian, BY, Germany
Bremen, HB, Germany
Martinsried, BY 82152, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Enrollment Status: Withdrawn
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drugs: Blinatumomab, Lymphocyte Infusion
Study Phase: Phase 2
Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Dendritic Cells Transfected With RNA Encoding Leukemia-associated Antigens
Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Dendritic Cells Transfected With RNA Encoding Leukemia-associated Antigens
Enrollment Status: Completed
Publish Date: October 12, 2018
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

226 Total Publications

Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.
Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.
Journal: Infection
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Subklewe's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile